Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series

Palbociclib is a potent cyclin-dependent kinase (CDK)4/6 inhibitor that disrupts cell cycle progression and has been recently approved in combination with an aromatase inhibitor or fulvestrant as first- and second-line treatment in hormone receptor (HR)(+), human epidermal growth factor receptor (HE...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Clin Oncol
Main Authors: Schettini, Francesco, Santo, Irene De, Rea, Carmen G., Viggiani, Martina, Buono, Giuseppe, Angelis, Carmine De, Cardalesi, Cinzia, Lauria, Rossella, Giuliano, Mario, Forestieri, Valeria, Thomas, Guglielmo, Maione, Pierfrancesco, Limite, Gennaro, Accurso, Antonello, Malorni, Luca, Placido, Sabino De, Arpino, Grazia
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2020
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7087462/
https://ncbi.nlm.nih.gov/pubmed/32257203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.2016
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados